 This randomized phase II trial studies how well bevacizumab with or without anti-endoglin monoclonal antibody TRC105 TRC105 works in treating patients with kidney cancer that has spread to other parts of the body metastatic. Monoclonal antibodies, such as bevacizumab and anti-endoglin monoclonal antibody TRC105, may block tumor growth in different ways by targeting certain cells. 